Fobrepodacin (SPR720) disodium is an orally active and potent phosphate proagent of SPR719 (VXc-486; ). Fobrepodacin disodium has potent bactericidal activities in vivo.
Fobrepodacin disodium (oral gavage; 10, 30, 100 mg/kg; once per day; 5 times per week for 4 weeks) reduces the mycobacterial burden in a model of chronic tuberculosis infection in mice[1].
Fobrepodacin disodium (oral; 100 mg/kg; once per day; 5 days per week, for 8 weeks) improves the bactericidal activities of antimycobacterial drugs[1].
References:
[1]. Locher CP, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.Antimicrob Agents Chemother. 2015 Mar;59(3):1455-65.